Scholars Central

Conference abstractPublished 26 Oct 2015

Bioequivalence study of two rizatriptan formulations after single-dose administration to healthy male volunteers using liquid chromatography-tandem mass spectrometry (LC-MS/MS)

Authors: Ahmed H Elshafeey, Amany O Kamel

1Cairo University, Egypt 2Ain Shams University, Egypt 3Genuine Research Center, Egypt

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Objective: The aim of this study was to assess the bioequivalence of two commercial 10 mg tablet formulations of rizatriptan, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist indicated for the acute treatment of migraine attacks using a newly developed and validated LC-MS/MS assay. Methods: A simple, sensitive and specific LC-ESI/MS method was developed and validated for the determination of rizatriptan in human plasma in positive mode using the transitions m/z 270.6-->201.6 for rizatriptan and m/z 384.07-->100.1 for the internal standard. Rizatriptan and the internal standard were isolated from plasma samples by liquid-liquid extraction. The chromatographic separation was accomplished on a Luna C18 (phenomenex) (50x4.6) mm, 5 Ã?¼m with mobile phase consisting of acetonitrile: ammonium acetate (70:30 v/v) and 0.1% formic acid. A bioequivalence study was carried out in 24 healthy adult male volunteers using a single-dose, randomized, 2-way crossover design under fasting conditions. Both the test product and the reference product were administered after an overnight fast on two treatment days, separated by a 2-week washout period. After dosing, serial blood samples were collected for 12 hours. Statistical analysis of the pharmacokinetic parameters Cmax, AUC0-12, AUC0-âÂ?Â? was conducted to determine bioequivalence. Results: Intra-day and inter-day assay precision was acceptable. The lower limit of quantification was 0.1 ng/mL. Accuracy was observed over a linear range of 0.1-100 ng/mL. The differences between the two products did not reach statistical significance with 90% CIs of 91.3-112.6, 101.6-111.2 and 102.0-111.6 for Cmax, AUC0-12 and AUC0-âÂ?Â?, respectively. The test/reference ratio of these parameters was within the acceptance range of the FDA criterion for bioequivalence. Both formulations were apparently well absorbed from the gastrointestinal tract (i.e., no specific gastrointestinal tract-related adverse events were reported). Conclusions: The validated method offered increased sensitivity and wide linear concentration range. This method was successfully adopted for the evaluation of bioequivalence of two rizatriptan products after single dose administration to 24 volunteers.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • SubjectPharmaceutical Sciences
  • SubjectChemistry
  • BylineArticles whose byline prints “Ahmed H Elshafeey”
  • BylineArticles whose byline prints “Amany O Kamel”